CRH PLC
2 April 2001
2/04/01 UK: CRH PLC RESULT OF EQUITY ISSUE - CORRECTION STATEMENT
CRH plc 2 April 2001
Not for release, publication or distribution in or into the United States,
Canada, Australia, Japan or Sweden
CRH PLC ('CRH')
CORRECTION TO ACCEPTANCE LEVEL
94.7 PER CENT. ACCEPTANCE OF 1 FOR 4 RIGHTS ISSUE
Further to the announcement made on 29 March 2001, the Board of CRH announces
that valid acceptances, being acceptances received by 3.00 p.m. on 27 March
2001, had been received in respect of 98,093,316 Rights Shares, representing
approximately 94.7 per cent. of the 103,622,311 Rights Shares offered to
Qualifying Shareholders at euro 10.50 per share.
The Company was notified today by its registrars that there was an error in
the previously announced acceptance level of 86.7 per cent. The registrars are
considering how best to correct this error, which may or may not involve the
purchase of CRH shares.
For Qualifying non-CREST Shareholders it is expected that definitive share
certificates in respect of the new CRH Shares will be despatched on or before
26 April 2001. For Qualifying CREST Shareholders it is expected that the
Company's registrars will instruct CREST to credit the appropriate CREST
Member Accounts on 20 April 2001.
For further information please contact:
Capita Corporate Registrars plc
Albert Farrell 00 353 1 661 7300
CRH
Harry Sheridan, Finance Director 00 353 1 404 1000
Myles Lee, General Manager Finance 00 353 1 404 1000
UBS Warburg
Paul Nicholls, Corporate Finance 00 44 207 568 2016
Philip Shelley, Capital Markets 00 44 207 568 2730
Davy Stockbrokers
Kyran McLaughlin, Head of Equities 00 353 1 614 8949
Paul Burke, Head of Investor Relations 00 353 1 614 8965
CRH plc, Belgard Castle, Clondalkin, Dublin 22, Ireland
TELEPHONE +353 1 404 1000
FAX +353 1 404 1007
Additional information
UBS Warburg and Davy acted as underwriters and financial advisers to the
Company with regard to the Rights Issue. This announcement has been issued by
and is the sole responsibility of the Company. It has been approved by UBS
Warburg which is regulated in the United Kingdom by The Securities and Futures
Authority Limited, solely for the purposes of Section 57 of The Financial
Services Act 1986 and by Davy which is regulated by the Central Bank of
Ireland pursuant to the Investment Intermediaries Act, 1995 and the Stock
Exchange Act, 1995 of Ireland.
UBS Warburg and Davy acted exclusively for CRH and no-one else in connection
with the Rights Issue and will not be responsible to anyone other than CRH for
providing the protections afforded to customers of UBS Warburg or Davy or for
providing advice in relation to the Rights Issue or any matter referred to
herein.
These materials are not for distribution, directly or indirectly, in or into
the United States. These materials are not an offer of securities for sale
into the United States. The securities are not being registered under the US
Securities Act of 1933 and may not be offered or sold in the United States or
to, or for the account or benefit of, US persons (as such terms are defined in
Regulation S under such Act) unless they are registered or exempt from
registration. No public offering of securities is being made into the United
States.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.